JP6785239B2 - 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物 - Google Patents

抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物 Download PDF

Info

Publication number
JP6785239B2
JP6785239B2 JP2017548368A JP2017548368A JP6785239B2 JP 6785239 B2 JP6785239 B2 JP 6785239B2 JP 2017548368 A JP2017548368 A JP 2017548368A JP 2017548368 A JP2017548368 A JP 2017548368A JP 6785239 B2 JP6785239 B2 JP 6785239B2
Authority
JP
Japan
Prior art keywords
acetaminophen
antibody
protein
protein adduct
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017548368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538786A5 (enExample
JP2017538786A (ja
Inventor
ディーン・ダブリュー・ロバーツ
ローラ・ジェイムズ
ジャック・ヒンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arkansas Childrens Hospital Research Institute Inc
BioVentures LLC
Original Assignee
Arkansas Childrens Hospital Research Institute Inc
BioVentures LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arkansas Childrens Hospital Research Institute Inc, BioVentures LLC filed Critical Arkansas Childrens Hospital Research Institute Inc
Publication of JP2017538786A publication Critical patent/JP2017538786A/ja
Publication of JP2017538786A5 publication Critical patent/JP2017538786A5/ja
Application granted granted Critical
Publication of JP6785239B2 publication Critical patent/JP6785239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
JP2017548368A 2014-12-03 2015-12-03 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物 Active JP6785239B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086923P 2014-12-03 2014-12-03
US62/086,923 2014-12-03
PCT/US2015/063786 WO2016090163A2 (en) 2014-12-03 2015-12-03 Anti-acetaminophen antibodies and acetaminophen protein adducts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020123616A Division JP7072022B2 (ja) 2014-12-03 2020-07-20 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物

Publications (3)

Publication Number Publication Date
JP2017538786A JP2017538786A (ja) 2017-12-28
JP2017538786A5 JP2017538786A5 (enExample) 2019-11-21
JP6785239B2 true JP6785239B2 (ja) 2020-11-18

Family

ID=56092671

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017548368A Active JP6785239B2 (ja) 2014-12-03 2015-12-03 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物
JP2020123616A Active JP7072022B2 (ja) 2014-12-03 2020-07-20 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020123616A Active JP7072022B2 (ja) 2014-12-03 2020-07-20 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物

Country Status (7)

Country Link
US (2) US10570216B2 (enExample)
EP (1) EP3227681B1 (enExample)
JP (2) JP6785239B2 (enExample)
AU (2) AU2015358373B2 (enExample)
CA (1) CA2967037A1 (enExample)
ES (1) ES2841904T3 (enExample)
WO (1) WO2016090163A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123574A1 (en) 2014-02-14 2015-08-20 The Board Of Trustees Of The University Of Arkansas Acetaminophen protein adducts and methods of use thereof
CA2967037A1 (en) 2014-12-03 2016-06-09 Bioventures, Llc Anti-acetaminophen antibodies and acetaminophen protein adducts
CN112980808B (zh) * 2019-12-12 2024-10-29 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
CN113248596B (zh) * 2021-04-15 2022-12-16 华南农业大学 一种可同时检测对乙酰氨基酚和非那西丁的人工抗原、抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5103021A (en) 1982-04-02 1992-04-07 Syntex (U.S.A.) Inc. Acetaminophen analogs, antigens, and antibodies
US4424150A (en) 1982-04-02 1984-01-03 Syva Company Acetaminophen analogs, antigens, and antibodies
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
ES2181734T3 (es) 1990-11-20 2003-03-01 Dade Behring Marburg Gmbh Ensayo inmunologico de ciclosporina.
US6905882B2 (en) 1992-05-21 2005-06-14 Biosite, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5747352A (en) 1994-05-23 1998-05-05 Beckman Instruments, Inc. Reagents and methods for the rapid and quantitative assay of pharmacological agents
US5620890A (en) * 1995-03-14 1997-04-15 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to hygromycin B and the method of making the same
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
WO2009097133A2 (en) * 2008-01-30 2009-08-06 Monsanto Technology, Llc Transgenic plants with enhanced agronomic traits
WO2009099580A2 (en) 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
US20090263839A1 (en) 2008-04-21 2009-10-22 Board Of Trustees Of The University Of Arkansas Acetaminophen-protein adduct assay device and method
US9012723B2 (en) * 2009-01-16 2015-04-21 Monsanto Technology Llc Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits
SG178348A1 (en) 2009-08-19 2012-03-29 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
DK2993183T3 (da) * 2010-02-16 2020-03-30 Oesterreichische Akademie Der Wss Anti-hpv e7-antistoffer
US20110214205A1 (en) 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
CN103688176A (zh) 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
EP2841575B1 (en) * 2012-04-27 2019-06-26 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
WO2015123574A1 (en) 2014-02-14 2015-08-20 The Board Of Trustees Of The University Of Arkansas Acetaminophen protein adducts and methods of use thereof
CA2967037A1 (en) 2014-12-03 2016-06-09 Bioventures, Llc Anti-acetaminophen antibodies and acetaminophen protein adducts

Also Published As

Publication number Publication date
ES2841904T3 (es) 2021-07-12
EP3227681A2 (en) 2017-10-11
EP3227681B1 (en) 2020-10-21
US20170362340A1 (en) 2017-12-21
AU2015358373B2 (en) 2021-05-27
AU2021215156A1 (en) 2021-09-02
WO2016090163A3 (en) 2016-08-25
JP2020189843A (ja) 2020-11-26
AU2015358373A1 (en) 2017-05-25
WO2016090163A2 (en) 2016-06-09
EP3227681A4 (en) 2018-06-13
CA2967037A1 (en) 2016-06-09
US11566081B2 (en) 2023-01-31
JP2017538786A (ja) 2017-12-28
JP7072022B2 (ja) 2022-05-19
US10570216B2 (en) 2020-02-25
AU2015358373A9 (en) 2021-05-27
US20200131278A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
JP7072022B2 (ja) 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物
CN110383068A (zh) 评估患者样品中uch-l1状态的改进方法
US20240368669A1 (en) Acetaminophen protein adducts and methods of use thereof
CN118725123B (zh) 抗胃蛋白酶原ⅱ抗体、检测胃蛋白酶原ⅱ的试剂和试剂盒
US10060925B2 (en) Miox antibody and assay
HK1242422A1 (en) Anti-acetaminophen antibodies and acetaminophen protein adducts
HK1242422B (en) Anti-acetaminophen antibodies and acetaminophen protein adducts
CN119019551B (zh) 抗cTnI抗体、检测cTnI的试剂和试剂盒
CN119504989B (zh) 一种抗心肌肌钙蛋白i抗体及其应用
CN118725124B (zh) 抗胃蛋白酶原ⅱ抗体、检测胃蛋白酶原ⅱ的试剂和试剂盒
CN117751288A (zh) 评价儿科受试者的脑损伤的方法
CN120188044A (zh) 用于区分轻度创伤性脑损伤与超轻度创伤性脑损伤的生物标志物和方法
CN118715440A (zh) 诊断脑损伤的方法和系统
CN119331097A (zh) 一种抗间日疟原虫乳酸脱氢酶抗体及其应用
HK1234307A1 (en) Acetaminophen protein adducts and methods of use thereof
HK40015192A (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
HK1234307B (en) Acetaminophen protein adducts and methods of use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201026

R150 Certificate of patent or registration of utility model

Ref document number: 6785239

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250